Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

BACKGROUND: Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering FcγRIII on natural kil...

Descripción completa

Detalles Bibliográficos
Autores principales: Beano, Alessandra, Signorino, Elena, Evangelista, Andrea, Brusa, Davide, Mistrangelo, Marinella, Polimeni, Maria Antonia, Spadi, Rosella, Donadio, Michela, Ciuffreda, Libero, Matera, Lina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2415031/
https://www.ncbi.nlm.nih.gov/pubmed/18485193
http://dx.doi.org/10.1186/1479-5876-6-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2415031/
https://www.ncbi.nlm.nih.gov/pubmed/18485193
http://dx.doi.org/10.1186/1479-5876-6-25

Ejemplares similares